IDO1 and renal cell adenocarcinoma: Studies trying to correlate IDO1 levels with response to ICPI regimens have found that in certain tumors like stage IV melanoma and renal cell cancer treated with anti-PD-1 therapy, increase in Kyn/Trp during therapy compared to baseline was seen to be associated with significantly reduced progression-free survival18.